RxDoctor Payments Data

Christopher Russo, MD

Cardiovascular Disease · Springfield, MANPI 1235456385

Payments from drug & device makers

$1,735in general payments, 2019–2025

Across 85 payments — averaging $20.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$607
  • Novartis$423
  • E.r. Squibb & Sons, L.L.C.$224
  • Bridgebio Pharma, Inc.$110
  • Medtronic$97
  • Boehringer Ingelheim$44
  • plus $229 from 9 others

What the payments were for

  • Food & beverage$1,735100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,735 in reported general payments places this provider in the 50th percentile of 750 cardiovascular disease providers in Massachusetts.

See all cardiovascular disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$200,828
Medicare patients
1,703
Services billed
3,191

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban446$545,964
EntrestoSacubitril/Valsartan152$205,495
XareltoRivaroxaban27$34,046
Repatha SureclickEvolocumab27$26,808
FarxigaDapagliflozin Propanediol19$21,613
BrilintaTicagrelor18$16,483
Metoprolol Succinate426$7,754
Rosuvastatin Calcium168$5,653
Diltiazem 24hr Er (Cd)Diltiazem Hcl97$4,766
Atorvastatin Calcium245$4,317
Carvedilol290$3,429
Isosorbide Mononitrate ErIsosorbide Mononitrate129$2,995
ClopidogrelClopidogrel Bisulfate128$2,478
Ezetimibe45$2,304
Torsemide77$2,115

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$607$545,964446 claims
NovartisEntresto$423$205,495152 claims
AstraZenecaFarxiga, Brilinta$38$38,09637 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 750 cardiovascular disease providers in Massachusetts.

Other cardiovascular disease in Springfield

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →